We are seeking participants for a clinical study to test the safety and effectiveness of encapsulated mesalamine pellets, an investigational medication, for maintenance of remission of mild to moderate ulcerative colitis. The study is comparing the investigational medication to placebo in people who have been diagnosed with ulcerative colitis that is in remission.

To qualify for the study, you must at least meet the conditions listed below:

·        You must be at least 18 years old.

·        You must be in remission from ulcerative colitis for at least one month but no longer than 12 months.

·        You must not have a history of allergy or intolerance to aspirin, mesalamine or other salicylates.

·        You must not have phenylketonuria.

·        You must not have received immunosuppressive therapy within 30 days prior to screening, or oral, IV, or topical rectal corticosteroids within 30 days prior to screening.

·        You must not have had any prior bowel surgery, excepting appendectomy.

For more information please contact:

Nancy Campbell

Phone #: 336-547-1739

nancy.campbell@mosescone.com

Site Address:  LeBauer Research Associates
  520 N. Elam Avenue, 3rd Floor
  Greensboro, NC  27403